News

Filter

Current filters:

None

28 to 37 of 98134 results

Bristol-Myers acquires rights to Novo Nordisk program focused on autoimmune diseases

Bristol-Myers acquires rights to Novo Nordisk program focused on autoimmune diseases

24-03-2015

US pharma major Bristol-Myers Squibb has agreed to acquire from Danish diabetes care giant Novo Nordisk…

BiotechnologyBristol-Myers SquibbGlobalImmunologicalsLicensingNovo Nordisk

Merck halts Keytruda study on positive results in melanoma

24-03-2015

US pharma giant Merck & Co says it will discontinue a study of its cancer drug Keytruda (pembrolizumab)…

BiotechnologyKeytrudaMerck & CoOncologyResearch

New enzalutamide presented by Astellas and Medivation at EAU

24-03-2015

Japanese pharma major Astellas Pharma and US drugmaker Medivation have presented new data from the Phase…

Astellas PharmaenzalutamideMedivationOncologyPharmaceuticalResearchXtandi

USA’s HHS seeks to develop improved anthrax vaccine

24-03-2015

Advanced development is underway on an improved anthrax vaccine that could provide protection in fewer…

BioThraxEmergent BioSolutionsFinancialNuThraxPharmaceuticalResearchUSAVaccines

Ono Pharma gets South Korea approval of Opdivo

24-03-2015

Japanese drugmaker Ono Pharmaceutical has received approval from South Korea’s Ministry of Food and…

BiotechnologyBristol-Myers SquibbOncologyOno PharmaceuticalOpdivoRegulationSouth Korea

Janssen acquires UK virtual biopharma firm XO1

24-03-2015

US health care giant Johnson & Johnson subsidiary Janssen Pharmaceuticals, has acquired XO1 Limited,…

BiotechnologyCardio-vascularichorcumabJanssenJohnson & JohnsonMergers & AcquisitionsUKXO1 Limited

ThromboGenics announces positive data from 24-month followup study of Jetrea

ThromboGenics announces positive data from 24-month followup study of Jetrea

24-03-2015

Ophthalmic medicine specialist ThromboGenics has announced positive top-line results from its study of…

JetreaOphthalmicsPharmaceuticalResearchThromboGenics

Cardio3 Biosciences opens US manufacturing facility

Cardio3 Biosciences opens US manufacturing facility

24-03-2015

European cell therapy specialist Cardio3 BioSciences is to open a new USA-based manufacturing facility…

BiotechnologyCardio3 BioSciencesCardio3 BioSciencesProductionUSA

Teva's anti-migraine drug TEV-48125 achieves primary and secondary endpoints at Phase IIb

Teva's anti-migraine drug TEV-48125 achieves primary and secondary endpoints at Phase IIb

24-03-2015

Israel-based Teva Pharmaceutical Industries says that its investigational drug TEV-48125 achieved the…

AnalgesiaIsraelNeurologicalPharmaceuticalResearchTEV-48125Teva

28 to 37 of 98134 results

Back to top